Skip to content

Dare Bioscience (DARE) Stock Surges On Bill & Melinda Gates Foundation Grant

Sam Boughedda
Sam Boughedda trader
Updated 7 Jul 2021

Practice Stock Trading Your Capitals Is At Risk
Dare Bioscience (NASDAQ: DARE)

Dare Bioscience (NASDAQ: DARE) shares are surging premarket after the company was awarded a new grant of up to $48.95 million from the Bill & Melinda Gates Foundation.


The grant is to help support the technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans.

DARE-LARC1 is the company’s investigational user-controlled, long-acting reversible contraceptive.

An initial payment of $11.45 million will be paid in July, with additional payments contingent on the DARE-LARC1 program’s achievement of specified development and reporting milestones.

Dare Bioscience’s share price has jumped 56.5% to $2.38 premarket on the news.

Should You Invest in Dare Bioscience Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Sam Boughedda
Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.